Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,224B 71.26B 63.82B 58.7B 53.19B 99.43B 6,766B 101B 700B 281B 3,559B 267B 262B P/E 2026 *
22x
P/E 2027 * 19.5x
Enterprise Value 10,199B 64.75B 57.99B 53.34B 48.33B 90.35B 6,148B 92.04B 636B 255B 3,234B 243B 238B EV / Sales 2026 *
7.32x
EV / Sales 2027 * 6.61x
Free-Float
38.12%
Yield 2026 *
1.98%
Yield 2027 * 2.24%
1 day+2.54%
1 week+3.14%
Current month+9.59%
1 month+11.91%
3 months-3.49%
6 months-14.08%
Current year-17.24%
1 week 6,522
Extreme 6522
6,897
1 month 5,974
Extreme 5974
6,897
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,331
Extreme 4331
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+3.14%+0.13%+52.69% 69.35B
+3.19%+11.31%+67.86%+150.58% 1,224B
-0.73%+3.56%+44.51%+85.81% 662B
+1.41%+3.24%+29.22%+107.83% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+2.93%+73.30%+45.62% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+6.09%+59.59%+77.06% 249B
+3.06%+9.38%+44.11%+119.47% 205B
Average +2.01%+2.36%+42.06%+80.63% 424.62B
Weighted average by Cap. +1.63%+2.99%+50.18%+97.91%

Financials

2026 *2027 *
Net sales 1,393B 8.84B 7.92B 7.28B 6.6B 12.34B 840B 12.57B 86.86B 34.87B 442B 33.18B 32.48B 1,522B 9.66B 8.65B 7.96B 7.21B 13.48B 917B 13.73B 94.92B 38.11B 483B 36.26B 35.49B
Net income 510B 3.24B 2.9B 2.67B 2.41B 4.51B 307B 4.6B 31.78B 12.76B 162B 12.14B 11.88B 577B 3.66B 3.28B 3.02B 2.73B 5.11B 348B 5.21B 35.98B 14.44B 183B 13.74B 13.45B
Net Debt -1,025B -6.51B -5.83B -5.36B -4.86B -9.08B -618B -9.25B -63.93B -25.66B -325B -24.42B -23.9B -1,165B -7.39B -6.62B -6.09B -5.52B -10.32B -702B -10.51B -72.64B -29.16B -369B -27.75B -27.16B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
30/10/26 JP¥6,822.00 +2.54% 3,076,400
29/10/26 JP¥6,653.00 +0.59% 4,547,300
28/10/26 JP¥6,614.00 -1.11% 3,542,700
27/10/26 JP¥6,688.00 -3.03% 3,220,000
26/10/26 JP¥6,897.00 +1.50% 3,324,200
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,822.00JPY
Average target price
8,446.67JPY
Spread / Average Target
+23.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Chugai Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4519 Stock